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CAPD in Australia
There are currently 25 renal units in Australia involved in a
continuous ambulatory peritoneal dialysis (CAPD) program.
The total number of patients on CAPD as of December31, 1981,
was 210 with 89 patients in Victoria and 46 in New South Wales.
(A complete breakdown on a state-by-state basis is given in
Table 1.) In December 1980 there were approximately 140
patients on CAPD creating a 50% increase for the year in the
number of CAPD patients. The increase in the number of CAPD
patients will continue, but the expected increase rate is a little
less at 30 to 40%, so that the total number of patients at the end
of 1982 will be about 300 patients or about 20 CAPD patients per
million.
As a comparison, there are about 1,500 patients in Australia
with functioning grafts and about 1,675 dialysis patients, which
include CAPD, intermittent peritoneal dialysis (IPD), and he-
modialysis (HD). CAPD presently accounts for nearly 12.5% of
the total of dialysis patients, or 6.6% of all kidney patients
compared to 9% and 4.7%, respectively, a year ago.
The major problems experienced with the technique during
1981 have been catheter site infections and, as in most other
countries, recurrent peritonitis. Catheter site infection has been
a relatively recent problem which can require catheter revision,
causing a reassessment of techniques of both catheter care and
initial catheter insertion.
The significance of peritonitis problems varies from unit to
unit. Qualitatively, those units with the least experience gener-
ally tend to have the worst results. Unfortunately, peritonitis
data at this time are still being reported on the basis of the
number of episodes per patient-month. As we and other investi-
gators have indicated [1, 21, this is not an entirely satisfactory
approach and it would be better statistically to compare units by
using life-table analysis; this obviates current difficulties associ-
ated with the distribution of episodes within the patient popula-
tion and temporal distribution within individual patients [21. In
addition, rational statistical comparisons can be made between
units, countries, or whatever, using the log rank method of Peto
et al [31. Although we preferred use of the life-table analysis, we
were unable, due to practical limitations at this time, to obtain
enough data to perform this type of analysis. So, for what it may
be worth, the incidence of peritonitis during 1981 varied from a
severe case experience of nearly one episode every 3 months to
one episode every 10 patient-months. The majority of the
patients use four bag exchanges per day.
There has also been a rather high attrition rate on the
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technique or poor technique survival, which is partially explain-
able by the comparatively active transplant program in this
country where about 48% of the patients, who have suffered
chronic uremia, have functioning grafts. However, the major
explanation for the high technique failure has been recurrent
peritonitis. A mean technique survival figure for the country is
difficult to determine; the ideal way to report these data would
also be with use of individual life-table analyses. We hope that
this will be done in the future. However, if transplant cases are
eliminated from the data, the mean technique survival rate in
Australia would be about 70% on an annual basis.
We are hoping that microbial filters may be the answer to
peritonitis, at least on a short-term basis. As reported recently
by Slingeneyer et al [4j the use of 0.22-xm filters can significant-
ly reduce the incidence of peritonitis. This system which uses a
90 filter (Millipore Twin, Bedford, Massachusetts) has been
modified by the Millipore company which nows has a filter set
available for selective clinical trials. We are currently evaluat-
ing this system (Peridex); it is too early to report firm data but
initial experiences in the United States appear to confirm the
data from Mion' s group in Montpellier [41.
The age distribution in patients is also somewhat skewed:
The treatment is still preferred for the very young and the very
old. This in itself may partially explain the figures on technique
survival. An old patient with reduced manual dexterity, poor
vision, and possible cardiovascular disease is not likely to be a
good candidate for any form of renal replacement therapy. Age
distribution should, therefore, be considered in comparing
CAPD experience with other forms of renal replacement
therapy.
We have no specific data to report based on 1981 experi-
ences. We previously reported [5] that acceptable dietary
protein intake (DPI of 0.9 to 1.1 g/kg/24 hr) could be maintained
during 2 years of CAPD. We also found that protein and amino
acid dialysate losses were relatively stable on long-term CAPD
at 7 3 g124 hr and 3 0.8 g/24 hr, respectively. However, we
feel that the nutritional aspects of CAPD do need careful
monitoring and an acceptable DPI should probably be around
1.2 gIkgI24 hr [61. We have also seen that there may be
clearance deterioration in long-term CAPD in some patients [7];
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a This state includes the Northern Territory.
this is not necessarily associated with recurrent peritonitis and
it could occur in up to 20% of the patients [7]. On the other
hand, the bulk of patients in our 1-year experiencc in this area
maintain clearance and show no evidence of deterioration in the
mass transfer capacity of the peritoneum, It is not known
whether or not patients who have lost mass transfer may
recover if the peritoneum is rested.
In summary, during the year ending in December 1981, there
was a 50% growth in the number of patients on CAPD during a
time whcn thc overall growth in kidney patients in Australia
was 13%. The growth in CAPD is expected to slow down a little
in 1981, but the total number of additional patients will be
approximately thc same as in 1981, that is, a further 80 to 90
patients will he initiated to CAPD during 1981. As indicated, the
major problem with the treatment is still peritonitis, but we are
cautiously optimistic that in-line microbial filters will help to
alleviate this problem.
GAPD in Europe
Although less spectacular than what may have been observed
in the United States, the growth of CAPD in Europe has been
substantial in the last 2 years.
The Registry of the European Dialysis and Transplant Asso-
ciation (EDTA) reported that by December 31, 1980, 32% of all
treatment centers in Europe had begun the use of CAPD, with
the highest percentage (>80%) in the United Kingdom [81.
Figure 1 shows the situation in different European countries.
Of all living patients, over 5% were being treated with CAPD
in the United Kingdom and Switzerland, 4% in Belgium, 3.5%
in Sweden, and approximately 1% in The Netherlands, Spain
and East Germany (Fig. 2).
The majority of the patients were on CAPD for a short time,
27% for less than 3 months, and 76% for less than 1 year. Only
2.5% had been on CAPD for more than 2 years.
Interesting data on peritonitis were also collected by the
EDTA Registry. Of those who were treated for 3 months, over
one-half had no episodes of peritonitis and one-third had
between one and three episodes. In the patients who were
treated for longer periods, one-quarter never had peritonitis,
even among those treated for more than 2 years. The proportion
with multiple episodes increased in those on treatment for a
longer time.
The frequency of peritonitis in diabetic patients was no higher
than in nondiabetie patients. Age did not seem to be related to
the incidence of peritonitis episodes.
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The well-known high dropout rate with CAPD is a matter of
concern. In Figure 3, actuarial survival methods have been
used, showing a survival of 65% on CAPD at 2 years and a
cumulative dropout of 29% at 1 year and 51% at 2 years.
The causes of discontinuing CAPD were: (1) abdominal
problems (peritonitis, abdominal pain, back pain, inadequate
dialysis) in about 39% in the first year and 47% in the second
year, (2) psychological problems (unable to cope, patient re-
fused, family refused) accounted for 16% in the first year and
8% in the second year, and (3) change to another treatment
occurred in 33% in the first year and 28% in the second year.
Peritonitis as a cause of dropout occurred in 31% in the first
year and 35% in the second year. The incidence of this
complication may decrease with better instructions to patients
and improved technical devices for CAPD. Toward this goal,
locking connectors for CAPD started to be used more frequent-
ly in 1981.
As for the future trend of CAPD in Europe, there is no doubt
but that its use has increased in 1981. In Belgium and The
Netherlands, the number of patients treated with CAPD in 1981
was about twice the number so treated in 1980. A further rise is
anticipated for 1982 in these two countries and presumably also
Table 1. CAPD distribution in Australia, December, 1981
No. of No. of CAPD
State centers patients
Approximate
population
millions
New South Wales 10 46 5.6
Victoria 6 89 3.9
Queensland 3 25 2.3
South Australiaa 3 23 1 .4
Western Australia 2 18 1.3
Tasmania 1 9 0.4
Total 25 210 14.9
%
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Fig. 1. Percentage of centers in Europe performing CAPE) on Decetnber
31, 1980. (Reprinted with the permission of the EDTA Registry.)
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in other European countries. It is reasonable to assume that at
least 10% of all European dialysis patients will soon be receiv-
ing CAPD.
CAPD in the United States
According to figures obtained from Baxter-Travenol Labora-
tories, Deerfield, Illinois, there were more than 6,000 patients
receiving CAPD therapy from over 500 CAPD centers in the
United States as of August 1982 (personal communication). The
National Institutes of Health have sponsored a National CAPD
Registry [9] which began registering patients on CAPD in
January 1981. As of August 1982 nearly 4,000 patients were
registered. Followup data are being collected on registered
patients and additional registration continues. It is too early to
comment on results of the total effort which is still in its
beginning stages.
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Fig. 3. Actuarial survival of patients on CAPD in Europe with separate
and combined calculations of cumulative mortality and dropout rates.
(Reprinted with the permission of the EDTA Registry.)
During 1981, prior to activation of the Registry, 14 selected
centers participated in a pilot phase collection of followup data
to test the feasibility of the registry format. The centers were
selected on the basis of experience and the size of their CAPD
programs. It cannot be emphasized too strongly that the results
of the pilot study may not be indicative of a more widespread
experience. Patients at these centers who were undergoing
CAPD at the start of 1981, or who began CAPD during this
period, were registered and followed quarterly thereafter. Data
are available from 567 patients monitored for 320 patient-years
during the calendar period January 1, 1981; to December 31,
1981. Detailed reports of the outcome were mailed to all centers
participating in the pilot effort. The following represents sum-
maries of some of the collected data.
Pilot study population. Figure 4 shows the age, race, and sex
of the 567 patients registered in the pilot study during 1981. The
average time since patients began some type of dialysis therapy
was 30.5 29 (SD) months, with a range of 0.5 to 195. The
average time since beginning CAPD therapy was 14 9
months, with a range of 0.4 to 55 months.
Patients entered CAPD from different forms of previous
therapy: 37.9% from hemodialysis, 36.3% from no previous
dialysis therapy, 22.2% from IPD, and 3.5% from a failed
transplant.
Pilot followup data. At least one followup data form was
received for each of the 567 patients. All expected followup
forms were submitted for 88% of the population at the time of
this analysis; many of the missing forms were due to late
submission of the final report by two centers.
1,728 patients started CAPD
00
0a-
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Fig 2. Percentage of all living patients in Europe on CAPD December
31, 1980. (Reprinted with the permission of the EDTA Registry.)
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Table 2 shows the annualized rates for selected outcome
measurements per patient-year in this population as a whole
and for 95 nondeath dropouts. Note that the nondeath dropouts
demonstrate higher rates of all complications listed.
Table 3 shows the distribution of days hospitalized into four
specified categories as a percentage of total hospital days in all
patients. Hospital days were monitored from April 1, 1981, to
December 31, 1981. Dialysis-related complications accounted
for nearly one-half of the hospital days. Many of these patients
have cardiovascular disease and other medical problems as
indicated by Table 3.
Table 4 shows that nearly 25% of the pilot study patients were
diabetic; most of the insulin-using diabetic patients adminis-
tered insulin by the intraperitoneal route entirely.
Table 5 summarizes life-table analyses [31 of important out-
come measurements in the pilot study, included as examples of
analyses to be completed with the national data. Projections
from the pilot phase should be considered as preliminary. The
numbers shown after the completion of indicated months on
CAPD are the cumulative percentages of patients at risk during
respective intervals in the status indicated. These differ for each
outcome, and ranges are given for brevity. These early projec-
tions show a cumulative patient survival on CAPD of 89.5% at I
year. The cumulative percent of patients remaining on CAPD at
1 year is 59.5%. Reasons for dropout could include death and all
the reasons for leaving CAPD. Although the numbers must be
considered preliminary, they are compatible with the dropout
rates seen in Australia and Europe. The cumulative existence
on CAPD without peritonitis is 30.8% of the patients at the end
Table 4. Diabetic status (percent of 566 patients) (Pilot Study)
Nondiabetic 77.0
Diabetic
Intraperitoneal insulin
Subcutaneous insulin
No insulin
Insulin routes mixed, or unknown
of 1 year. Much higher percentages will escape exit and tunnel
infections and catheter replacement. The cumulative percent-
age escaping hospitalization during the first year is only 19.. 7%.
There are many reasons for dropout and hospitalization in this
population and not all are related to problems with CAPD. Fair
comparisons cannot he made with other forms of dialysis
therapy at the present time; randomized prospective compari-
sons of similar populations (matched for age, cardiovascular
disease, and diabetes) are not available.
Table 6 shows the last reported status as a percentage of 567
patients as of December 31, 1981. Patients spent varying
periods of time on CAPD during the 12-month interval, and
these numbers represent absolute percentages rather than actu-
arial analyses. Most patients who left CAPD transferred to
hemodialysis (10.4%). Of the patients, 7.1% had died. Very
small percentages went to IPD, kidney transplantation, or no
longer required dialysis.
Table 7 shows the reasons for leaving CAPD other than
death, transplantation, or the return of renal function. These
numbers represent percentages of 69 patients in the pilot study
who left CAPD during 1981 for reasons other than those
indicated above. The most common reason (34.8%) was related
to medical problems not considered a complication of CAPD
per se hut those that interfered with the patient performing this
type of self-treatment. Stroke, progressive debilitation with
malignancy, visual difficulties with diabetes mellitus, and debili-
tating arthritis are examples. The second largest category
pertained to recurrent peritonitis and technique problems that
related more to compliance and motivation than physical dis-
ability. The third category pertained to socioeconomic reasons
and patient preference. These included reasons related to
lifestyle whereby patients and/or their families decided that
CAPD was not for them.
Table 8 shows summary results of selected frequency distri-
butions of outcome measurements related to patient rehabilita-
tion and complications.. Numbers represent the percentage of
pilot study patients followed during 1981 who fall into catego-
ries indicated. For example, as a crude index of mobility, 86.2%
of the patients could go outside their homes without aid, and
54.6% of the patients could perform work above and beyond
self-care and hygiene. In reports to participating centers, these
frequency distributions divide each of the outcomes into many
0)
0)
a.
C
0)
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z
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Table 3. Distribution of days hospitalized (percent of 6,540 days)
(Pilot Study)
Dialysis-related complications
Cardiovascular problems
Other medical problems
Training
48.1
10.5
32.9
8.5
Aqe, years
Fig. 4. Age, rare, and sex distribution of 567patients in lbs Pilot Study.
The graph shows the 1981 results of reports received by April 7, l982.
Table 2. Annualized rates for selected outcome measurements (Pilot
Study)
Measurement All patients Nnndeath dropouts
Patients 567 95
Patient-years 320 4(1
Peritonitis 1.98 4.16
Exit or tunnel infeetionsa 0.72 I .00
Catheter replacements 0.40 t).70
Hospital admissionsa 2.52 4,79
Hospital days (any 25.9 52.3
reason)'
a Per patient year.
13.1
4.4
3.0
2.5
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Table 5. Life-table analysesa (Pilot Study)
Months on CAPD
Patients at
riskb
Remained
alive on
CAPD
Still on
CAPD
No
peritonitis
No exit/
tunnel
infections
No catheter
replacement
Not
hospitalized
3 184 to 194 97.8 92.1 70.7 79.6 87.6 55.2
6 68 to 122 92.8 78.5 49.4 69,9 84.0 39.6
9 28 to 60 89.5 68.0 41.1 64.5 72.0 24.1
12 6 to 16 89.5 59.5 30.8 64.5 66.0 19.7
a Numbers for outcomes represent cumulative percentages of patients at risk.
b Numbers differ for each column; the range is given.
Still on CAPD 76.1%
Hemodialysis 10.4%
Dead 7.1%
Kidney transplant 3.0%
IPD 2.1%
Return of renal function 0.9%
Stopped dialysis 0.4%
Unknown 0.2%
Table 7. Reasons for leaving CAPD other than death, transplant, or
return of renal function (percent of 69 patients) (Pilot Study)
Medical problems not CAPD-related
Recurring peritonitis or technique
problems
Socioeconomic and patient
preference
Poor control of chemistries or fluid
Other, or unknown
Table 8. Frequency distributions for selected outcomes (percent of
567 patients) (Pilot Study)
Rehabilitation
Able to go out alone 86.2%
Works more than 10 hr/week 54.6%
No hospital admissions 36.2%
Complications
No catheter replacement 82.2%
No exit/tunnel infection 75.3%
No peritonitis 48.5%
subcategories, such as the percentage of patients with one, two,
and three or more episodes of peritonitis.
Comments relative to the United States experience. Dropout
rates and hospitalizations are only partially explained by perito-
nitis and dialysis complications. In all areas of the world, many
CAPD programs probably begin with problem patients. Fre-
quently, CAPD is offered as an alternative to death. Often there
is little else to offer. Thus, all of these considerations must be
taken into account in evaluating these data. Advanced technol-
ogies are appearing and should improve these outcomes. With
present equipment it is important to keep in mind that there are
more than a few patients on CAPD without complications for
over a year or more.
Summary. CAPD experiences from three continents—Aus-
tralia, Europe, and the United States—have been highlighted
for the year 1981. Hopefully, improved technology will reduce
peritonitis rates. Dropout rates should decrease with reduced
peritonitis rates. Most likely, dropout rates are also related to
the inclusion of many patients with a variety of debilitating
medical problems in CAPD programs. It will be important to
continue to monitor CAPD outcome measurements to assess
the impact of technical advances and increasing experience in
the years to come.
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